卡培他滨对综合治疗失败的乳腺癌疗效观察  

Therapeutic Effect Observation of Applying Xeloda in Breast Cancer after Failure of Combination Therapy

作　　者：王志刚[1] 姚杰[1] 王洋[1] 李鸣芳[1] 

机构地区：[1]解放军第一六一医院肿瘤科,武汉430010

出　　处：《肿瘤防治研究》2007年第7期528-529,共2页Cancer Research on Prevention and Treatment

摘　　要：目的观察卡培他滨对综合治疗失败的复发转移性乳腺癌的疗效及毒副反应。方法36例病人按照希罗达+基础治疗的方案实施治疗。希罗达2500mg/(m2.d),每日2次餐后半小时口服、连服2周,休息1周,第4周重复上周期化疗。每2个周期评价1次疗效,病情进展停药。基础治疗包括营养支持治疗、癌痛治疗、贫血治疗、骨转移治疗等。结果全部病人均完成6个周期以上化疗。CR2例,PR15例,SD11例,PD8例,有效率47.2%,疾病控制率77.8%,中位无进展生存期8.2个月。1、2年生存率分别为66.7%、25%。主要的毒副反应为可逆性的手足综合征、皮肤色素沉着。结论对于综合治疗失败的复发转移性乳腺癌选择单药希罗达化疗仍是一个较好的治疗方案,患者的依从性、耐受性及安全性较好,值得临床推广应用。Objective To explore the therapeutic effect, the toxic and side effects of xeloda capecitabine treatment in breast cancer after failure of combination therapy. Methods 36 patients accepted the therapeutic alliance plan of xeloda monotherapy together with basic therapy. 2 500mg/m^2 xeloda peros b. i. d, half hour after meals, two weeks applied and one week free, repeated in the fourth week. Effect evaluation was made after each two cycles, medicine discontinued when state of disease progressed. Basic therapy including nutritional supporting therapy, anti-anemia therapy, anti-bone-metastasis therapy, alleviating pain therapy, etc, had been applied at equal pace. Results All patients had finished chemotherapy of more than 6 cycles. CR in 2 case, PR in 15 cases, SD in 11 case, PD in 8 cases. Effective rate was 47. 2%, disease control rate was 77.8%, meso-life span without disease progressing was 8. 2 months. 1 year and 2 years survival rate was 66. 7% and 25% respectively. The main toxic and side effects observed were reversible hand-foot syndrome and skin pigmentation. Conclusion The treatment applying xeloda monotherapy has been proved still a fine choice in breast cancer when combination therapy defeated. The compliance, tolerance and safty are all good in patients.

关 键 词：希罗达 乳腺癌 手足综合征 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]